Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Predictive biomarkers in breast cancer

Cynthia X. Ma • 7 Dec 2021
SABCS 2021
Breast Cancer Pembrolizumab
KEYNOTE-522

Cynthia X. Ma, MD, PhD, Washington University in St. Louis, St. Louis, MO, discusses the field of predictive biomarkers in breast cancer, including PD-L1 which is associated with response to immunotherapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Cynthia X. Ma

3:44
ALTERNATE: neoadjuvant endocrine treatment in ER+/HER2- breast cancer
Cynthia X. Ma • 7 Dec 2021
1:01
FLEX: real-world data platform bringing precision medicine to the clinic
Cynthia X. Ma • 7 Dec 2021
3:01
ALTERNATE: neoadjuvant chemotherapy in ER+ HER2- breast cancer
Cynthia X. Ma • 3 Dec 2020
0:53
What to expect in breast cancer in 2021
Cynthia X. Ma • 3 Dec 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals